Retrospective, real-world results showed that patients treated with oral decitabine and cedazuridine and standard parenteral hypomethylating agents (HMAs) for myelodysplastic syndrome (MDS) demonstrated similar levels of comorbidities and disease burden to patients treated with intravenous (IV)/subcutaneous (SC) HMAs.
Oral decitabine/cedazuridine and parenteral hypomethylating agents were associated with similar levels of comorbidities and disease burden in patients with myelodysplastic syndrome.